NeuroBlu Data 26R5 adds 83.2M clinical notes and 91.1M measurements since 26R4, with Alzheimer’s Disease reaching 641K patients and Dementia reaching 2.2M. This release updates NeuroBlu Medication Insights (beta) with three structured tables, maps the Young Mania Rating Scale (YMRS) for Bipolar Disorder, adds PCL-5 and MDS-UPDRS to the scales extracted from clinical notes, and expands the Depressive Disorders NLP model to around 900K new patients.
26R5 Dataset: Adds 83.2M Notes and 91.1M Measurements
26R5 adds 83.2M clinical notes and 91.1M measurements since 26R4. Neurological coverage keeps growing, with Alzheimer’s Disease reaching 641K patients and Dementia reaching 2.2M.
NeuroBlu Medication Insights: Now in Three Structured Tables
Medication Insights uses Holmusk’s proprietary Medication Management LLM (MedLLM) to extract medication changes, clinical rationale, and reported side effects from neuropsychiatric notes. In 26R5, that data is reorganized into three tables to make it easier to use:
nlp_note_drug: medication changes captured from notesnlp_note_side_effects: reported side effects, now mapped to OMOPnlp_note_change_reasons: reasons for change, now standardized and categorizedMedication Insights allows to look at why behind medication changes, supporting treatment-switching, tolerability, and persistence research.
New Bipolar Disorder Scale (YMRS) and Increased Scales Coverage
The Young Mania Rating Scale (YMRS) is now mapped in the measurement table. YMRS data comes from structured measurements, including total and item scores, and from regex-based extraction from clinical notes. This gives Bipolar Disorder research a validated measure of mania severity over time. Scale extractors now also pull PCL-5 (for PTSD screening) and MDS-UPDRS (for Parkinson's evaluation) scores from clinical notes.
NLP Expansion: Depression and Suicidality
The Depressive Disorders NLP model adds around 810K new patients with evidence of at least one suicidality label and around 88K new patients with evidence of at least one core symptom label. These labels turn free-text narrative into structured criteria you can filter on directly.
26R5 in Summary
NeuroBlu Data 26R5 delivers 83.2M new clinical notes, 91.1M new measurements, Medication Insights in beta, new YMRS mapping for Bipolar Disorder, PCL-5 and MDS-UPDRS extraction from notes, and around 900K new patients with depression and suicidality NLP evidence.
Log in to explore 26R5, or request a demo to see it in action.
Interested in Medication Insights? Talk to our team about beta access.
